Long-term Follow-up Study of BRL-101 in the Treatment of Transfusion-dependent β-thalassemia
Status: Recruiting
Location: See all (7) locations...
Intervention Type: Other
Study Type: Observational
SUMMARY
Observe long-term safety risk and long-term efficacy after intravenous infusion of BRL-101 in TDT subjects.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 3
Maximum Age: 35
Healthy Volunteers: f
View:
• Provision of written informed consent for this study by subjects, or as applicable, subject's parent(s)/legal guardian(s)
• Treated with BRL-101 for therapy of transfusion-dependent β-thalassemia.
Locations
Other Locations
China
Xiangya Hospital of Central South University
RECRUITING
Changsha
The First Affiliated Hospital of GUANGXI MEDICAL UNIVERSITY
RECRUITING
Guangxi
Nanfang Hospital, Southern Medical University
ACTIVE_NOT_RECRUITING
Guangzhou
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
NOT_YET_RECRUITING
Guangzhou
No. 923 Hospital of Joint Support Force of Chinese People 's Liberation Army Hospital
NOT_YET_RECRUITING
Nanning
Shenzhen Children 's Hospital
NOT_YET_RECRUITING
Shenzhen
Tianjin Institute of Hematology
RECRUITING
Tianjin
Contact Information
Primary
Rongmei Liang, phD
rongmeiliang@brlmed.com
021-64340008
Time Frame
Start Date: 2024-12-08
Estimated Completion Date: 2038-10-15
Participants
Target number of participants: 45
Treatments
BRL-101
All patients who have received BRL-101
Related Therapeutic Areas
Sponsors
Collaborators: The 923rd Hospital of Joint Logistics Support Force of People's Liberation Army, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University, Chinese Academy of Medical Sciences, Nanfang Hospital, Southern Medical University, Shenzhen Children's Hospital, First Affiliated Hospital of Guangxi Medical University, Xiangya Hospital of Central South University
Leads: Bioray Laboratories